BioSpace News Archive

While it has yet to reach clinical trials, preclinical results with the company’s specially-tailored adeno-associated virus have been fortuitously auspicious.

Products getting regulatory approval and hitting the market doesn’t always spell success for companies, especially during a global pandemic. Michigan-based Esperion has learned that lesson all too well.

Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced installation of its Genesis Robotic Magnetic Navigation system at Princess Grace Hospital Center in Monaco, a leading center of research and training for the treatment of cardiac arrhythmias.

BiomX Inc., a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic bacteria, announced results from its Phase 2 cosmetic clinical study assessing the potential of BX001 to improve the appearance of skin in acne prone subjects.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today announced that vonoprazan successfully met its primary endpoints and key secondary superiority endpoints in PHALCON-EE, a pivotal phase 3 trial evaluating vonoprazan versus lansoprazole for the treatment of erosive esophagitis.

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it has entered into an exclusive licensing agreement with Antares Pharma, Inc. to commercialize TLANDO in the United States.

Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, announced the appointment of Clay Siegall, Ph.D. as its Chairman of the Board of Directors.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that new data suggesting a systemic immune response can be generated with its lead clinical product candidate, PH-762, after local administration.

Bicycle Therapeutics plc today announced the closing on Friday, October 15, 2021 of its underwritten public offering of 3,726,852 American Depositary Shares (“ADSs”)

Atsena Therapeutics today unveiled its preclinical gene therapy program for X-linked retinoschisis (XLRS), a monogenic disease caused by mutations in the RS1 gene.